US EditionAntengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025
- Antengene will present clinical data on ATG-037 and ATG-008 for CPI-resistant solid tumors at ASCO 2025 in Chicago from May 30 to June 3.
- The presentations report ongoing STAMINA-01 and TORCH-2 trials assessing ATG-037 plus pembrolizumab and ATG-008 plus toripalimab in patients with advanced, refractory solid tumors.
- ATG-037, an oral CD73 inhibitor, combined with pembrolizumab showed a 36.4% ORR and 100% disease control rate in CPI-resistant melanoma, while ATG-008 plus toripalimab achieved a 22.2% ORR in CPI-resistant cervical cancer.
- As of April and November 2024, 43 patients received ATG-037 monotherapy or combination therapy with treatment-related adverse events in 56% and 61% respectively, and one serious immune-mediated hepatitis case was reported.
- These results indicate manageable safety profiles and highlight the potential of ATG-037 and ATG-008 combinations as novel options for difficult-to-treat CPI-resistant cancers.
Insights by Ground AI
Does this summary seem wrong?
76 Articles
76 Articles
All
Left
7
Center
29
Right
6
Daily Journal+75 Reposted by 75 other sources
Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025
ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01…
·Cherokee County, United States
Read Full ArticleCoverage Details
Total News Sources76
Leaning Left7Leaning Right6Center29Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 17%
C 69%
14%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage